Research and analysis

Hydroxychloroquine or chloroquine, in combination with macrolide antibiotics: review of epidemiological data for cardiovascular safety

Public Assessment Report on our review of epidemiological data for cardiovascular safety.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 15 February 2022

Documents

Hydroxychloroquine or chloroquine, in combination with macrolide antibiotics: review of epidemiological data for cardiovascular safety

HTML

Hydroxychloroquine or chloroquine, in combination with macrolide antibiotics: review of epidemiological data for cardiovascular safety

PDF, 272 KB, 24 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Annex 1. Product information updates for medicines containing hydroxychloroquine

PDF, 54.3 KB, 1 page

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Annex 2. Product information updates for medicines containing chloroquine

PDF, 53.9 KB, 1 page

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Annex 3. Product information updates for medicines containing azithromycin

PDF, 54.1 KB, 1 page

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Annex 4: Product information updates for medicines containing clarithromycin or erythromycin

PDF, 53.2 KB, 1 page

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The aim of our Safety Public Assessment Reports is to present evidence-based assessments of safety issues for a particular drug or drug class.

The report provides a summary of the review of available safety data on the cardiovascular safety of hydroxychloroquine and chloroquine when these medicines are used on their own or in combination with the macrolide antibiotics azithromycin, clarithromycin or erythromycin.

Published 15 February 2022